logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Osimertinib for EGFR-positive non-small cell lung cancer – adjuvant

< Back

Osimertinib for EGFR-positive non-small cell lung cancer – adjuvant

Drugs

Cancer and Palliative Care

August 2020


Osimertinib is in clinical development as an adjuvant treatment for resectable, early stage non-small cell lung cancer (NSCLC). Lung cancer is one of the most common and serious types of cancer and NSCLC is the most common type of lung cancer. An adjuvant treatment is an additional cancer treatment given after the primary treatment, to lower the risk of the cancer returning. Resectable cancer means that the cancer can be removed by surgery, which means the cancer is normally in earlier stages. A proportion of patients have mutations to the protein epidermal growth factor receptor (EGFR) which controls cell growth. There are currently no recommended EGFR-targeted therapies for early stage NSCLC.
Osimertinib is an inhibitor of EGFR, which binds specifically to mutant forms of EGFR to inhibit growth of tumour cells. Osimertinib is administered as an oral tablet and has demonstrated both safety and effectiveness in a phase III clinical trial. Osimertinib is already approved for advanced NSCLC and if licensed for the early stage disease, it will offer an additional treatment option for patients with EGFR-positive NSCLC, after complete tumour resection.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts